In the past week, DNTH stock has gone down by -10.85%, with a monthly decline of -4.70% and a quarterly plunge of -7.28%. The volatility ratio for the week is 9.03%, and the volatility levels for the last 30 days are 5.40% for Dianthus Therapeutics Inc The simple moving average for the past 20 days is -5.05% for DNTH’s stock, with a 1.82% simple moving average for the past 200 days.
Is It Worth Investing in Dianthus Therapeutics Inc (NASDAQ: DNTH) Right Now?
The stock has a 36-month beta value of 1.78. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DNTH is 20.25M, and at present, short sellers hold a 25.17% of that float. On November 14, 2024, the average trading volume of DNTH was 201.59K shares.
DNTH) stock’s latest price update
The stock price of Dianthus Therapeutics Inc (NASDAQ: DNTH) has jumped by 1.16 compared to previous close of 26.35. Despite this, the company has seen a fall of -10.85% in its stock price over the last five trading days. zacks.com reported 2024-11-07 that Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago.
Analysts’ Opinion of DNTH
Many brokerage firms have already submitted their reports for DNTH stocks, with Oppenheimer repeating the rating for DNTH by listing it as a “Outperform.” The predicted price for DNTH in the upcoming period, according to Oppenheimer is $48 based on the research report published on October 03, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see DNTH reach a price target of $58. The rating they have provided for DNTH stocks is “Outperform” according to the report published on July 26th, 2024.
DNTH Trading at -3.67% from the 50-Day Moving Average
After a stumble in the market that brought DNTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.07% of loss for the given period.
Volatility was left at 5.40%, however, over the last 30 days, the volatility rate increased by 9.03%, as shares sank -4.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.90% lower at present.
During the last 5 trading sessions, DNTH fell by -10.07%, which changed the moving average for the period of 200-days by +41.53% in comparison to the 20-day moving average, which settled at $28.09. In addition, Dianthus Therapeutics Inc saw 156.31% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for DNTH
Current profitability levels for the company are sitting at:
- -25.96 for the present operating margin
- 0.9 for the gross margin
The net margin for Dianthus Therapeutics Inc stands at -21.01. The total capital return value is set at -0.24. Equity return is now at value -25.99, with -24.54 for asset returns.
Based on Dianthus Therapeutics Inc (DNTH), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -160.5.
Currently, EBITDA for the company is -48.17 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 239.47. The receivables turnover for the company is 2.47for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.30.
Conclusion
To sum up, Dianthus Therapeutics Inc (DNTH) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
